3-肼基噻吩-2-羧酸甲酯 | 75681-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-肼基噻吩-2-羧酸甲酯
• 英文名称: methyl 3-hydrazinylthiophene-2-carboxylate
• 英文别名: Methyl 3-Hydrazinothiophene-2-Carboxylate
• CAS: 75681-13-9
• 化学式: C₆H₈N₂O₂S
• mdl: MFCD00052080
• 分子量: 172.208
• InChiKey: RWGYQWWIXLVGDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  92.6
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	Methyl 3-hydrazinothiophene-2-carboxylate tech Material Safety Data Sheet
Synonym:
CAS:	75681-13-9

Section 1 - Chemical Product MSDS Name:Methyl 3-hydrazinothiophene-2-carboxylate tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
75681-13-9	Methyl 3-hydrazinothiophene-2-carboxyl		unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 75681-13-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: yellow
Odor: characteristic odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 69 - 70 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H8N2O2S
Molecular Weight: 172

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 75681-13-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 3-hydrazinothiophene-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 75681-13-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 75681-13-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 75681-13-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-肼基噻吩-2-羧酸甲酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 3-(3-Oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-thiophene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  噻吩并吡唑并喹啉：苯并二氮杂receptor受体的强效激动剂和反向激动剂。

  摘要：

  一系列2-（thien-3-yl）-和2-（thien-2-yl）-2,5-dihydro-3H-pyrazolo [4,3-c] quinolin-3的合成及构效关系-报告一个。与地西epa相比，许多化合物对受体的亲和力高1个数量级。平面度是与苯并二氮杂receptor受体结合的结构要求之一。激动剂和反向激动剂的活性分别基于戊烯四唑诱导的惊厥的抑制或促进进行评估。噻吩-3-基化合物表现出反向激动剂活性，而具有5'-烷基的噻吩-2-基类似物表现出激动剂活性。喹啉部分上的取代不增强体内活性。

  DOI：

  10.1021/jm00117a012
• 作为产物：
  描述：

  methyl 3-hydrazinylthiophene-2-carboxylate;hydrochloride 、 sodium hydroxide 以88%的产率得到
  参考文献：
  名称：

  HUDDELSTON P. R.; BARKER J. M.; ADAMCZEWSKA Y. Z., J. CHEM. RES. SYNOP., 1980, NO 7, 238-239

  摘要：

  DOI：

文献信息

• Triazolone derivatives
  申请人：Clark Richard

  公开号：US20080015199A1

  公开（公告）日：2008-01-17

  A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]

  以下一般式（1）表示的化合物，其盐或上述化合物的水合物是一种新型化合物，可用于治疗和/或预防与血栓形成相关的疾病，并且具有适当的物理化学稳定性，更安全。 [其中R1a，R1b，R1c和R1d分别独立表示氢等；R2表示可选择取代的苯基等；R3表示可选择取代的C6-10芳基等；Z1和Z2分别独立表示氢]
• Anti-infective agents
  申请人：——

  公开号：US20040087577A1

  公开（公告）日：2004-05-06

  Compounds having the formula 1 are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.

  具有公式1的化合物是丙型肝炎（HCV）聚合酶抑制剂。还公开了一种用于抑制丙型肝炎（HCV）聚合酶的组成和方法，用于制造这些化合物的过程，以及在这些过程中使用的合成中间体。
• THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES
  申请人：Kaplan Alan P.

  公开号：US20080306049A1

  公开（公告）日：2008-12-11

  The invention provides a novel chemical series of formula I, as well as methods of use thereof for binding to the benzodiazepine site of the GABA A receptor and modulating GABA A , and use of the compound of formula I for the treatment of GABA A receptor associated disorders. The general structure of formula I is shown below and can exist in tautomeric forms: The invention further provides a method of modulation of one or more GABA A subtypes in an animal comprising administering to the animal an effective amount of a compound of formula (I).

  这项发明提供了一种新颖的化学系列，其化学式为I，以及用于结合到GABA A 受体的苯二氮卓类位点并调节GABA A 的使用方法，以及用于治疗与GABA A 受体相关疾病的化合物的使用。化学式I的一般结构如下所示，并且可以存在互变异构体形式： 该发明还提供了一种在动物中调节一个或多个GABA A 亚型的方法，包括向动物投与化学式(I)化合物的有效量。
• Hydrazide and alkoxyamide angiogenesis inhibitors
  申请人：——

  公开号：US20020002152A1

  公开（公告）日：2002-01-03

  Compounds having the formula 1 are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

  具有以下化学式的化合物是蛋氨酸氨肽酶2型（MetAP2）抑制剂，对抑制血管生成有用。还公开了抑制MetAP2的组合物和在哺乳动物中抑制血管生成的方法。
• 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES
  申请人：Clark Richard

  公开号：US20090270433A1

  公开（公告）日：2009-10-29

  A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation. [wherein R 1 represents hydrogen, R 2 represents optionally substituted phenyl, etc., R 3 represents optionally substituted C6-10 aryl, etc.]

  下列通式(1)所代表的化合物或其盐具有丝氨酸蛋白酶抑制活性，尤其对凝血因子VIIa有着卓越的抑制活性。该化合物或其盐可作为治疗和/或预防与血栓形成相关的疾病的药物。【其中，R1代表氢，R2代表可选取代的苯基等，R3代表可选取代的C6-10芳基等】。